RxDoctor Payments Data

Deborah Johnson

Family · Morganton, NCNPI 1558750950

Payments from drug & device makers

$9,844in general payments, 2019–2025

Across 688 payments — averaging $14.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • Lilly USA, LLC$1K
  • Pfizer$832
  • Teva Pharmaceuticals USA, Inc.$735
  • AstraZeneca$549
  • plus $4K from 39 others

What the payments were for

  • Food & beverage$9,70199%
  • Education$1431%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$9,844 in reported general payments places this provider in the 95th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$12,095
Medicare patients
40
Services billed
238

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide38$55,185
MounjaroTirzepatide32$45,151
FarxigaDapagliflozin Propanediol14$23,701
TrulicityDulaglutide12$23,209
KerendiaFinerenone20$22,936
UbrelvyUbrogepant13$21,607
EliquisApixaban31$21,553
MyrbetriqMirabegron21$14,872
JardianceEmpagliflozin16$13,570
XareltoRivaroxaban16$13,491
SymbicortBudesonide/Formoterol Fumarate26$11,751
LinzessLinaclotide11$11,105
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$10,434
Xtampza ErOxycodone Myristate12$8,594
Stiolto RespimatTiotropium Br/Olodaterol Hcl14$7,648

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,025$68,36044 claims
Novo NordiskOzempic$1,422$55,18538 claims
AstraZenecaFarxiga, Symbicort$549$35,45340 claims
AbbVieUbrelvy, Linzess, Synthroid$1,650$33,29336 claims
Boehringer IngelheimJardiance, Stiolto Respimat, Spiriva Respimat$145$28,02444 claims
BayerKerendia$329$22,93620 claims
PfizerEliquis$832$21,55331 claims
Astellas Pharma US IncMyrbetriq$229$14,87221 claims
Johnson & JohnsonXarelto$64$13,49116 claims
GSKTrelegy Ellipta$127$10,43414 claims
Collegium Pharmaceutical, Inc.Xtampza Er$18$8,59412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,522 family providers in North Carolina.

Other family in Morganton

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →